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Specific germline activating point mutations in the gene encoding the tyrosine kinase receptor FGFR3 (fibro-
blast growth factor receptor 3) result in autosomal dominant human skeletal dysplasias. The identification in
multiple myeloma and in two epithelial cancers—bladder and cervical carcinomas—of somatic FGFR3
mutations identical to the germinal activating mutations found in skeletal dysplasias, together with functional
studies, have suggested an oncogenic role for this receptor. Although acanthosis nigricans, a benign skin
tumor, has been found in some syndromes associated with germinal activating mutations of FGFR3, the
role of activated FGFR3 in the epidermis has never been investigated. Here, we targeted an activated receptor
mutant (S249C FGFR3) to the basal cells of the epidermis of transgenic mice. Mice expressing the transgene
developed benign epidermal tumors with no sign of malignancy. These skin lesions had features in common
with acanthosis nigricans and other benign human skin tumors, including seborrheic keratosis, one of the
most common benign epidermal tumors in humans. We therefore screened a series of 62 cases of seborrheic
keratosis for FGFR3 mutations. A large proportion of these tumors (39%) harbored somatic activating FGFR3
mutations, identical to those associated with skeletal dysplasia syndromes and bladder and cervical
neoplasms. Our findings directly implicate FGFR3 activation as a major cause of benign epidermal tumors
in humans.
INTRODUCTION
Fibroblast growth factor receptor 3 (FGFR3) belongs to a class
of transmembrane tyrosine kinase receptors (FGFR1–4)
involved in signal transduction regulating cell growth, differ-
entiation, migration, wound healing and angiogenesis, depend-
ing on target cell type and developmental stage. These
receptors are glycoproteins composed of two or three extra-
cellular immunoglobulin (Ig)-like domains, a transmembrane
domain and a split tyrosine kinase domain. Ligand binding
induces receptor dimerization, leading to phosphorylation of
the kinase domain (1,2). Specific activating point mutations
affecting different domains of FGFR3 result in autosomal
dominant human skeletal dysplasias: craniosynostoses
(Crouzonodermoskeletal syndrome and Muenke craniosynos-
tosis) and dwarfing chondrodysplasias of various degrees of
severity (hypochondroplasia, achondroplasia, severe achon-
droplasia with developmental delay and acanthosis
nigricans—also known as ‘SADDAN’—and thanatophoric
dysplasia) (3,4). The degree of activation of FGFR3 is
Published by Oxford University Press 2005.
{
The authors wish it to be known that, in their opinion, the first three authors should be regarded as joint First Authors.
*To whom correspondence should be addressed. Tel: þ33 142346339; Fax: þ33 142346349; Email: francois.radvanyi@curie.fr
Human Molecular Genetics, 2005, Vol. 14, No. 9 1153–1160
doi:10.1093/hmg/ddi127
Advance Access published on March 16, 2005
correlated with the severity of dwarfing chondrodysplasias (5).
Functional studies have shown that some of these mutations
activate the receptor either by generating a cysteine residue
that can form an intermolecular disulfide bond leading to
ligand-independent dimerization of the receptor (R248C) or
by changing the conformation of the activation loop in the
tyrosine kinase of the receptor (K650/652E) (3,4). Additional
evidence consistent with FGFR3 playing a negative role in
bone growth has been obtained in several mouse models
including Fgfr3-deficient mice and mice harboring activating
mutations in FGFR3 (4). In contrast to this inhibitory role,
an oncogenic role has been proposed for FGFR3 in cancer.
Somatic activating FGFR3 mutations identical to those
found in skeletal dysplasias have been shown to be associated
with multiple myeloma and more recently with epithelial
malignancies (bladder and cervix carcinomas) (6–8).
Functional studies have provided several lines of evidence
supporting an oncogenic role for FGFR3: activated FGFR3
induces the malignant transformation of NIH3T3 fibroblasts
(9,10) and generates lymphoid malignancies in mice (11).
Although acanthosis nigricans, a benign skin epidermal
tumor, has been found in some syndromes associated with
germinal activating mutations of FGFR3 (Crouzonodermoske-
letal syndrome, SADDAN syndrome and rare long-surviving
thanatophoric dysplasia patients) (12–15), the role of acti-
vated FGFR3 in the epidermis has never been investigated.
We investigated the role of activated FGFR3 in the epider-
mis by targeting the expression of an activated receptor
(S249C FGFR3) to the basal layer of the epidermis, using
the bovine keratin 5 (K5) promoter (16,17). The S249C
mutation, which causes ligand-independent activation of the
receptor, is the most common FGFR3 mutation in carcinomas
(8,18,19). This mutation also causes thanaphoric dysplasia, a
syndrome associated with acanthosis nigricans in the rare
long-term survivors (14,15).
RESULTS
Transgenic mice expressing mutated FGFR3 (FGFR3
S249C) in the epidermis develop benign skin tumors
We targeted the expression of a mutated form of FGFR3
(FGFR3 S249C) to the epidermis using the keratin 5 promoter.
The K5-(S249C)FGFR3 construct was made by subcloning the
FGFR3 S249C cDNA (see Materials and Methods) into a
vector containing a 5.2 kb fragment of the bovine keratin 5
promoter, the rabbit b-globin intron 2 and the SV40 polyade-
nylation signal. This construct was then microinjected into
fertilized B6D2F1 mouse oocytes. Among the seven founders
obtained, four expressed the K5-(S249C)FGFR3 transgene in
the skin (data not shown). Three of these four founders devel-
oped a skin phenotype. These three founders were viable and
fertile and transmitted the transgene to their offspring in a
Mendelian fashion. The offspring developed a phenotype
indistinguishable from that of the founders. At the age of
3–4 months, the transgenic mice presented skin verrucous
tumors on the eyelids and the snout (Fig. 1A and B), which
then gradually extended from the snout to the throat. In
animals aged .5 months, another type of lesion appeared
on the upper trunk, characterized by a marked thickening of
Figure 1. Phenotype of K5-(S249C)FGFR3 transgenic mice. (A and B) Two K5-(S249C)FGFR3 transgenic mice (line 79) at 6 months of age. These mice exhibit
verrucous cauliflower-like lesions on the snout and the eyelids. These lesions are well demarcated, of symmetrical localization and occasionally display partial
pigmentation, as shown in (B). (C) Throat and upper chest skin lesions on a 10-month-old K5-(S249C)FGFR3 transgenic mouse (line 79) are shown. The throat
lesions resemble those on the snout in (A and B), areas of flat skin thickening with hair loss are clearly apparent on the upper chest. (D–F) Control littermates are
shown below each transgenic mouse.
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the skin and hair loss (Fig. 1C). None of the skin lesions arising
in the various transgenic lines showed any signs of regression.
In some old mice, a thickening of the tongue and palate was
observed. No lesions were observed in other tissues, although
some expressed the transgene including the forestomach and
the trachea (Supplementary Material Fig. S1).
Histological examination of the skin lesions revealed
common features, irrespective of body site and gross appear-
ance: (i) pronounced acanthosis (thickening of the nucleated
layers of the epithelium), (ii) hyperkeratosis (thickening of
the stratum corneum) with occasional parakeratosis (hyperker-
atosis, with retention of nuclei) and (iii) papillomatosis
(numerous projections of the dermal papillae) (Fig. 2). The
most exophytic lesions of the snout displayed a trabeculated
pattern, with rare keratin-filled invaginations and small
keratin cysts, which generally surrounded a hair shaft
(Fig. 2B). No abnormalities of the hair follicles or sebaceous
glands were observed. No histological features of malignancy
were detected: mitotic figures were rare and always localized
in the basal layer of the epidermis and cytological atypia was
not observed. The absence of malignancy was evident, even in
the lesions of transgenic mice .18 months old. Cell prolifer-
ation was studied by incorporation of the thymidine analog
5-bromo-2-deoxyuridine (BrdU). Consistent with the benign
nature of the lesions, proliferating cells were restricted to
the basal cell layer of the epidermis and to hair follicles in
both transgenic and control mice (Fig. 3). However, the
proportion of basal cells undergoing proliferation was signifi-
cantly higher in transgenic mouse epidermis than in control
skin (27 versus 1.8%, P , 0.0001).
Frequent FGFR3 mutations are found in a common
benign skin tumor in humans
The skin lesions observed in transgenic mice expressing
mutated FGFR3 displayed several histological features
(acanthosis, hyperkeratosis and papillomatosis) common to
benign human epidermal tumors including seborrheic kerato-
sis, one of the most common benign epidermal tumors in
humans. This lesion, which has no malignant potential, is
mainly located on the trunk and face and presents as two
histological types—the hyperkeratotic and the acanthotic
types. Seborrheic keratoses tend to appear in middle age and
become more common and numerous with advancing age.
We screened a series of 62 seborrheic keratoses for FGFR3
mutations by using single strand conformation polymorphism
(SSCP) analysis followed by DNA sequencing. The three
regions of FGFR3 (located in exon 7, 10, 15) known to
harbor most of the point mutations previously described in
multiple myeloma, bladder and cervical carcinomas and skel-
etal dysplasias were analyzed. We identified point mutations
in 24 samples (39%) (Fig. 4 and Table 1). Matched consti-
tutional DNA, available in 10 skin tumor cases with FGFR3
mutations, contained wild-type sequences demonstrating the
somatic nature of these mutations (Fig. 4) (data not shown).
We found no correlation among the presence of FGFR3
mutations, the sex or age of the patients, the location of the
tumors (P ¼ 0.21) or the histological type (acanthotic or
hyperkeratotic) (P ¼ 0.29). Among the four patients for
whom two seborrheic keratoses were analyzed, we found a
FGFR3 mutation in one of the two lesions for two patients
Figure 2. Tumor histology of K5-(S249C)FGFR3 transgenic mouse skin
lesions. (A, B and D) Hematoxylin, eosin and saffron sections of skin
lesions from the snout (A and B) and the trunk (D) of a transgenic K5-
(S249C)FGFR3 mouse. (C and E) Sections of normal snout (C) and trunk
(E) from a control littermate are shown for comparison. These skin lesions
showed various degrees of acanthosis, papillomatosis and hyperkeratosis.
Lesion in (B) is thicker than in (A) and shows interlacing strands (trabeculated
aspect) of basaloid and squamous cells enclosing hair follicles. The parakera-
tosis and spongiosis observed in (A) were probably caused by itching and
repetitive scratching of the lesion. Magnification 100  .
Figure 3. K5-(S249C)FGFR3 transgenic mice, tumor cell proliferation, as
assessed by BrdU labeling. Mice were injected with 5-bromodeoxyuridine
(BrdU), and tissue sections were analyzed by immunohistochemical staining
with an antibody against BrdU. Labeled cells were restricted to the basal
layer in both transgenic K5-(S249C)FGFR3 mice (A) and wild-type litter-
mates (B). Magnification 200  .
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(cases 47a and b and 53a and b), no FGFR3 mutation in either
lesion for one patient (case 55a and b) and a different FGFR3
mutation in each seborrheic keratosis for one patient (case 11a
and b) (Table 1).
The 24 mutations identified affected seven different codons:
R248C, S249C, G372C, S373C, Y375C, K652E and K652M
(Table 2). All these mutations were identical to the consti-
tutional mutations present in patients with thanatophoric dys-
plasia and SADDAN (3,20,21). With the exception of the
S373C mutation, all the mutations have already been
described as somatic mutations in multiple myeloma and in
bladder and cervical carcinomas (6–8,18,19). The mutations
in exon 7 (R248C and S249C) were located at the junction
between extracellular Ig-like domains II and III of FGFR3,
the mutations in exon 10 (G372C, S373C and Y375C) were
located in the transmembrane domain and the mutations in
exon 15 (K652E and K652M) were located in the second
part of the intracellular tyrosine kinase domain of FGFR3.
DISCUSSION
Since the identification of mutations of FGFR3 in human skel-
etal dysplasias, the role of FGFR3 in skeletal development has
attracted considerable attention (4). The recent identification
of somatic activating FGFR3 mutations in multiple
myeloma and in two epithelial cancers—bladder and cervix
carcinomas—has raised the question of an oncogenic role of
mutated FGFR3 in tumorigenesis (6–8). In hematopoietic
cells, functional studies have shown that mutated FGFR3
may contribute to the malignant phenotype (9–11). The onco-
genic potential of mutated FGFR3 has yet to be investigated in
bladder and cervix epithelia.
We show here that mutated FGFR3 can induce benign
tumors with no malignant potential in mouse epidermis. This
led us to identify frequent FGFR3 mutations in seborrheic ker-
atosis, one of the most frequent benign epidermal tumors in
older individuals. Here, we screened part of the coding
sequence of FGFR3 (exons 7, 10 and 15) containing most of
the mutations identified in severe forms of dwarfism and all
the mutations already identified in bladder and cervix carci-
nomas. However, we cannot totally exclude the presence in
seborrheic keratoses of FGFR3 mutations outside these exons.
Although the clonal nature of seborrheic keratoses has been
suggested (22), no molecular alterations had been reported in
these lesions. We report for the first time a molecular altera-
tion associated with this benign skin tumor. The FGFR3
mutations that we found in seborrheic keratosis are the same
as those found in thanatophoric dysplasia and SADDAN
syndrome. Interestingly, the rare long-surviving thanatophoric
dysplasia patients and all the patients with SADDAN syn-
drome develop acanthosis nigricans, a benign skin tumor
sharing histological similarities with seborrheic keratosis and
with the mouse skin lesions observed in our transgenic mice.
Our results in mice strongly suggest that the occurrence of
acanthosis nigricans observed in these human skeletal dis-
orders results directly from the expression of mutated
FGFR3 in the epidermis.
We expressed an activated form of FGFR3 in the mouse
epidermis by targeting the FGFR3 S249C transgene to the
epidermis with the keratin 5 promoter. A different
approach—targeted homologous recombination—has been
used in previous studies to generate several mouse models har-
boring a mutated endogenous FGFR3 gene (23–26). The
various mutations inserted corresponded to mutations found
in skeletal dysplasias, carcinomas and, as shown here, sebor-
rheic keratoses. Surprisingly, although the endogenous
mouse gene is expressed in the skin, no skin lesions have
been reported in these models. The absence of a skin pheno-
type may be due to the genetic background of the mice used
in these models, the level of expression of the mouse
FGFR3 gene, differences in the regulation of the mouse and
human promoters or slight differences between the mouse
and the human FGFR3.
The skin lesions observed in our transgenic mouse model
have several histological features in common with seborrheic
keratoses (acanthosis, hyperkeratosis and papillomatosis).
Human seborrheic keratoses characteristically display
keratin-filled structures (horn cysts and pseudo-horn cysts).
In the mouse model, horn cysts were present in some thick
lesions, but were less numerous and smaller than those in
human seborrheic keratoses. Furthermore, in mice, these
cysts always surrounded a hair. The differences between
human and mouse lesions may simply correspond to a differ-
ence between species. They may also be due to mutated
FGFR3 being under the control of the keratin 5 promoter in
the mouse model, whereas mutated FGFR3 is under the
control of its own promoter in human seborrheic keratoses.
The FGFR3 promoter gives suprabasal expression in resting
human skin and basal expression after wounding (27). In
human seborrheic keratosis, FGFR3 expression was observed
in both the basal and the suprabasal layers. In transgenic
mouse lesions, the mutated FGFR3 was observed in the
basal layer and in the first suprabasal layers (Claire
Dunois-Larde´ and Jean-Marie Gasc, unpublished results).
The induction of benign skin tumors by FGFR3 mutations
in mice, the occurrence of acanthosis nigricans in skeletal dys-
plasia syndromes caused by germinal FGFR3 mutations and
the identification of somatic FGFR3 mutations in seborrheic
Figure 4. Example of a somatic FGFR3 mutation in a seborrheic keratosis
sample. Sequencing revealed a missense mutation in codon 652
(AAG–. ATG) of FGFR3 in DNA from seborrheic keratosis 46 and a
wild-type sequence in a normal matched DNA sample.
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Table 1. Clinical data and FGFR3 mutations found in the 62 seborrheic keratoses
Case # Age (yr) Sex Location of the tumor Size (mm) Histological type FGFR3 codon FGFR3 Mutation
1 73 F Trunk 10 Acanthotic wt
2 64 F Face 10 Acanthotic 248 CGC! TGC
3 76 F Extremity 9 Hyperkeratotic wt
4 51 F Extremity 8 Hyperkeratotic wt
5 47 M Face 12 Acanthotic wt
6 51 M Face 8 Acanthotic 373 AGT! TGT
7 46 F Extremity 8 Acanthotic wt
8 56 M Trunk 10 Acanthotic wt
9 54 M Face 9 Hyperkeratotic 248 CGC! TGC
10 76 F Trunk 9 Acanthotic 249 TCC ! TGC
11a 91 F Trunk 12 Acanthotic 249 TCC ! TGC
b Trunk 15 Acanthotic 375 TAT ! TGT
12 59 F Trunk 15 Acanthotic wt
13 86 M Face 6 Hyperkeratotic wt
14 71 M Face 8 Acanthotic wt
15 66 F Trunk 8 Hyperkeratotic wt
16 54 F Face 10 Acanthotic 372 GGC ! TGC
17 53 F Trunk 7 Acanthotic wt
18 84 F Trunk 8 Hyperkeratotic 248 CGC! TGC
19 43 F Face 12 Acanthotic 652 AAG! ATG
20 59 F Trunk 15 Acanthotic wt
21 67 F Face 6 Acanthotic 372 GGC ! TGC
22 57 F Trunk 6 Hyperkeratotic wt
23 63 F Trunk 10 Acanthotic wt
24 44 F Trunk 4 Hyperkeratotic wt
25 72 F Trunk 13 Acanthotic 375 TAT ! TGT
26 74 M Face 6 Acanthotic wt
27 40 F Trunk 6 Acanthotic wt
28 88 F Trunk 7 Hyperkeratotic wt
29 67 F Face 7 Acanthotic wt
30 66 F Trunk 8 Hyperkeratotic wt
31 85 M Trunk 6 Acanthotic 248 CGC! TGC
32 83 F Trunk 5 Hyperkeratotic wt
33 67 F Face 8 Acanthotic 249 TCC ! TGC
34 31 F Trunk 3 Acanthotic 248 CGC! TGC
35 76 F Face 10 Hyperkeratotic wt
36 79 F Face 4 Acanthotic wt
37 49 F Trunk 6 Hyperkeratotic wt
38 63 F Face 15 Hyperkeratotic wt
39 76 F Trunk 6 Acanthotic wt
40 52 F Face 14 Hyperkeratotic wt
41 56 F Trunk 10 Acanthotic wt
42 59 M Face 18 Acanthotic wt
43 83 F Trunk 6 Hyperkeratotic 372 GGC ! TGC
44 30 F Trunk 10 Hyperkeratotic wt
45 77 F Trunk 4 Hyperkeratotic wt
46 31 F Trunk 5 Acanthotic 652 AAG! ATG
47a 79 M Face 11 Hyperkeratotic 373 AGT! TGT
b Face 4 Hyperkeratotic wt
48 67 F Trunk 6 Acanthotic 375 TAT ! TGT
49 65 F Trunk 15 Hyperkeratotic 373 AGT! TGT
50 79 F Trunk 7 Hyperkeratotic 652 AAG! ATG
51 75 F Face 14 Hyperkeratotic wt
52 70 F Face 15 Acanthotic 249 TCC ! TGC
53a 79 F Face 6 Hyperkeratotic 652 AAG! GAG
b Face 11 Hyperkeratotic wt
54 45 F Trunk 12 Acanthotic wt
55a 46 M Extremity 9 Hyperkeratotic wt
b Trunk 6 Acanthotic wt
56 76 F Face 9 Acanthotic wt
57 31 M Face 4 Acanthotic 375 TAT ! TGT
58 75 M Face 10 Hyperkeratotic 249 TCC ! TGC
F: female; M: male; wt: wild-type.
Two seborrheic keratoses were analyzed for cases 11, 47, 53 and 55.
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keratoses support a role for mutated FGFR3 in benign epider-
mal tumorigenesis. The fact that we did not identify FGFR3
mutations in a series of epidermal carcinomas (23 squamous
cell carcinomas and 22 basal cell carcinomas) (28) (data not
shown) suggests that the role of activated FGFR3 in the
epidermis is restricted to benign tumorigenesis. In the
bladder, although FGFR3 mutations are found in a significant
proportion of muscle-invasive carcinomas (15% of cases), it
should be noted that such mutations occur at high frequency
(.70% of cases) in low stage, low grade bladder carcinomas
(TaG1–TaG2) (18,29). In addition, a high frequency of
FGFR3 mutations was recently detected in urothelial
papilloma, a rare entity with little or no risk of developing
urothelial carcinomas (30,31).
The transgenic mouse model we have set up should be
useful for studying the mechanisms of benign tumorigenesis
and for developing new therapies targeting mutated FGFR3.
Although not life threatening, seborrheic keratoses can be
troublesome and annoying to the patient. They may become
irritated and itch. Often unattractive, or even disfiguring,
these lesions have a negative psychological impact—daily
reminders of aging. Anti-tyrosine kinase drugs have recently
been used successfully to treat several malignancies (32).
The identification of activating mutations of a tyrosine
kinase receptor in a significant proportion of seborrheic kera-
toses may provide new opportunities for the treatment of this
condition.
MATERIALS AND METHODS
Generation of K5-(S249C)FGFR3 transgenic mice
We targeted the expression of an activated FGFR3 carrying
the S249C mutation to the epidermis in mice, using the
50-regulatory region of the bovine keratin 5 gene (16).
The FGFR3b splice variant was used, as this is the main
form of FGFR3 in the murine epidermis and human epithelia
(33) (unpublished data). The S249C mutation, which causes
ligand-independent activation of the receptor, is the most
common mutation in carcinomas (8). The coding sequence
of the human FGFR3b cDNA was amplified by RT–PCR
from RNA of a normal urothelium, using the primers
50-CGGGGCTGCCTGAGGAC-30 and 50-TGCTAGGGACC
CCTCACATT-30. The PCR product was inserted into a cyto-
megalovirus promoter-driven pcDNAI/Neo expression vector
(Invitrogen, San Diego, CA, USA). The S249C mutation was
then introduced into this cloned FGFR3b cDNA as follows:
a 729 bp region of the FGFR3b cDNA carrying the S249C
mutation was amplified by RT–PCR from RNA of a bladder
carcinoma, using the primers 50-CGTCGTGGAGAACAAG
TTTGGCAG-30 and 50-CCGAGACAGCTCCCATTTG-30.
The Xho1–Aor51H1 fragment containing the mutation was
excised from the PCR product and inserted in place of the
corresponding sequence in the non-mutated FGFR3b con-
struct. The pK5-(S249C)FGFR3b construct was then obtained
by inserting the mutated FGFR3b cDNA excised with Xba I
and HindIII into the SnaBI site of the pBK5 expression
vector containing the 5.2 kb bovine keratin 5 (K5) regulatory
sequences, b-globin intron 2 and the 30 polyadenylation
sequences of SV40. All PCR-generated segments were
verified by sequencing both strands. The K5-(S249C)FGFR3
construct excised with Sal I and Not I was purified and micro-
injected into fertilized B6D2F1 oocytes. Genomic DNA was
extracted from mouse tails and screened by PCR for inte-
gration of the transgene. The care, housing and handling of
the mice conformed to the recommendations of the French
Ethics Committee and were overseen by authorized
investigators.
Histology of mouse tissues
Tissue samples from transgenic mice and wild-type littermates
matched with respect to sex and body site were collected and
fixed by overnight incubation at room temperature in freshly
prepared Methacarn (6 vol absolute methanol/3 vol
chloroform/1 vol acetic acid). The samples were embedded
in paraffin, and sections (5 mm) were cut and stained with
hematoxylin–eosin–saffron for histological analysis.
BrdU labeling
Transgenic mice (n ¼ 5) from line 79 and control littermates
(n ¼ 5) were injected (i.p.), with 0.25 mg g21 body weight
BrdU (Sigma). They were sacrificed 2 h later. BrdU immuno-
histochemistry was carried out with the BrdU in situ detection
kit (BD PharMingen, San Diego, CA, USA), using
the reagents and conditions suggested by the manufacturer.
The number of BrdU-labeled cells among 300 cells from the
basal epidermis layer was determined for each mouse.
Human skin samples
Alcohol/formalin/acetic acid-fixed paraffin-embedded speci-
mens of seborrheic keratoses were obtained from the Pathol-
ogy Department of the Institut Curie and cut into 8 mm
sections. One section was used for hematoxylin–eosin–
saffron staining, for distinguishing the tumor cell areas and
their subsequent microdissection from the remaining unstained
sections. Genomic DNA was isolated using the QIAmp tissue
kit (Qiagen), according to the manufacturer’s instructions.
Table 2. FGFR3 mutations in 62 seborrheic keratoses




248 742 7 CGC ! TGC Arg ! Cys 5
249 746 7 TCC ! TGC Ser ! Cys 5
372 (370) 1114 10 GGC ! TGC Gly! Cys 3
373 (371) 1117 10 AGT ! TGT Ser ! Cys 3
375 (373) 1124 10 TAT ! TGT Tyr ! Cys 4
652 (650) 1954 15 AAG ! GAG Lys! Glu 1
652 (650) 1955 15 AAG ! ATG Lys! Met 3
Codons and mutated nucleotides (nt position) are numbered according to
the open reading frame of the FGFR3b cDNA. This isoform, which is the
predominant form in epithelial cells, contains two more amino acids than
the FGFR3c isoform, which is found in bone. Codon numbers according
to the open reading frame of the FGFR3c cDNA are indicated in brackets.
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Mutation analyses
We used SSCP and sequencing to analyze the three regions of
FGFR3 in exons 7, 10 and 15 known to harbor most of the
point mutations previously described in multiple myeloma,
bladder and cervix carcinomas and skeletal dysplasias. SSCP
and sequence analysis were performed as previously described
(18), except that the following primer sequences were used:
50-AGTGGCGGTGGTGGTGAGGGAG-30 and 50-GACGTT
CCACATGTCACTGCGTGT-30 for exon 7; 50-CCTCAACG
CCCATGTCTTTGCAGC-30 and 50-GTTCTAGAGGGCGAA
GGGCGAGTTC-30 for exon 10 and 50-TGGTGACCGAGGA
CAACGTGATG-30 and 50-GTTGTGGCGGAAGGGTGTGG
GA-30 for exon 15.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG Online.
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